Navigation Links
Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds

d-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with the possibility that the FDA declines to schedule an advisory panel meeting to review our NDA; the FDA refuses to approve our NDA; because our Phase 3 clinical trial known as the SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial failed to meet its primary endpoint, the FDA may require additional data, analysis or studies before the NDA is approved by the FDA; the outcome of any discussions with the FDA; the initiation, timing, design, enrollment and cost of clinical trials; unexpected delays in clinical trials and preparation of materials for submission to the FDA as part of our NDA filing; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to obtain future financing and fund the preparation of our NDA filing and the product development of our pipeline; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2006 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
3. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
4. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:9/17/2014)... YORK , Sept. 17, 2014  Levi & ... in connection with possible claims of breaches of fiduciary ... To get more information, click here: ... you. If you own common stock in ... please contact Eduard Korsinsky, Esq. either via ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire-iReach/ -- ... white paper discussing improvements in the development ... structures for both normal and diseased tissue ... information, simplifies surgical procedures, lowers surgical costs ... surgical procedures. The clinical ...
(Date:9/17/2014)... , Sept. 17, 2014 Bronstein, Gewirtz & ... purchasers of the securities of PDL BioPharma, Inc. ("PDL ... -News).  Such investors are advised to contact Peretz ... Kimelman at info@bgandg.com or 212-697-6484. ... certain of its executives violated federal securities laws. ...
Breaking Medicine Technology:Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
(Date:9/17/2014)... 2014 The National Resident Matching Program ... a comprehensive analysis of the relationship between unique applicant ... The new edition is based on the 2014 ... U.S. allopathic medical school senior students and all other ... to provide this new edition of Charting Outcomes in ...
(Date:9/17/2014)... Los Angeles, CA (PRWEB) September 17, 2014 ... U.S. Food & Drug Administration report titled “Adverse ... Intranasal Splint as a Dermal Filler,” unapproved use ... filler injections has resulted in adverse reactions including ... acid based products with FDA approval for cosmetic ...
(Date:9/17/2014)... 17, 2014 Sunday night saw ... and ushered in a new national spokesperson for ... America Organization’s official national platform, Children’s Miracle ... newest National Goodwill Ambassador. , Kazantsev’s year in ... Network Hospitals across the U.S., visiting with patients ...
(Date:9/17/2014)... study was announced today that will analyze how ... wellness and contribute to healthy aging. , ... funded through a $10 million unrestricted gift from ... aims to identify lifestyle and environmental factors that ... as they age. WELL will be designed, conducted, ...
(Date:9/17/2014)... (HealthDay News) -- Social networking sites can help people ... people who are obese, sites like Twitter and Facebook ... from doctors as well as peers, researchers found. ... is that it offers the potential to be much ... compared to traditional approaches," the study,s lead author, Dr. ...
Breaking Medicine News(10 mins):Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3Health News:Simon Ourian, Kim Kardashian's Cosmetic Surgeon, Warns About Illegal Use of Expression as a Dermal Filler 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 3Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Social Networking Sites Can Help Obese Lose Weight: Study 2
... ST. PAUL / MINNEAPOLIS (April 29, 2008) Young ... sexual partners both online and offline have greater numbers of partners, ... rates than those who meet their partners exclusively online or offline, ... ...
... return of members, money to UHW-W,treasury from outside fund, ... local union United Healthcare Workers West (UHW-W) violated federal,law ... millions,of dollars in dues money to an outside fund ... today by SEIU in United States District,Court for the ...
... opportunities for buyer to, capitalize on ... YORK, April 29 Berkery Noyes announced today ... sale to HMP,Communications, a portfolio company of Alta ... investment in the new combined entity. Terms,of the ...
... levels increasing even within normal range associated with dangers ... of thyrotropin within the normal range may increase the ... Norwegian study finds. , Thyrotropin, a hormone produced by ... acts on the thyroid gland to stimulate its growth ...
... (ACP) -- the nations second-largest medical society , ... a continuing medical education (CME) meeting for general ... primary and subspecialty care to adult patients. More ... professionals, medical residents, fellows, and students. Internal Medicine ...
... Baptist Health System, one,of Alabama,s largest healthcare ... to bring together the health-improvement,needs of local employers ... its four hospitals. Aegis brings nearly 20 years, ... with the unique,healthcare needs of area employees., ...
Cached Medicine News:Health News:U of M study: Online intervention paramount for reducing HIV in high-risk population 2Health News:Top UHW-W Officers Violated Federal Law, Deceived Members in Diverting Millions in Dues Money to Outside Fund 2Health News:Top UHW-W Officers Violated Federal Law, Deceived Members in Diverting Millions in Dues Money to Outside Fund 3Health News:Top UHW-W Officers Violated Federal Law, Deceived Members in Diverting Millions in Dues Money to Outside Fund 4Health News:Berkery Noyes Represents Princeton Media Associates in Its Sale to HMP Communications/Alta 2Health News:Berkery Noyes Represents Princeton Media Associates in Its Sale to HMP Communications/Alta 3Health News:Pituitary Hormone May Boost Women's Heart Risk 2Health News:Internal Medicine 2008 media advisory 2Health News:Alabama's Baptist Health System and Aegis Health Group Partner to Address Local Employers Health-Management Concerns 2
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... The Repeater Plus, a handheld manual ... saving time on long series pipetting. Its ... exceptional support for research tasks, and its ... with repetitive work. The nine Combitips allow ...
eValuator fixed-curve diagnostic electrophysiology catheters offer an effective balance between clinical performance and cost....
The True Non-Compliant Balloon....
Medicine Products: